Starling Oncology, Inc. STLN
$6.94
$0.314.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.29M | -43.51M | -60.61M | -66.28M | -65.89M |
| Total Depreciation and Amortization | 6.81M | 6.78M | 6.94M | 7.02M | 6.87M |
| Total Amortization of Deferred Charges | 4.84M | 4.72M | 8.38M | 8.77M | 9.18M |
| Total Other Non-Cash Items | 8.26M | 11.08M | 19.37M | 20.45M | 15.61M |
| Change in Net Operating Assets | 16.71M | -876.00K | 1.33M | 6.41M | 24.04M |
| Cash from Operations | 328.00K | -21.81M | -24.59M | -23.63M | -10.19M |
| Capital Expenditure | -3.61M | -3.91M | -3.20M | -3.90M | -2.89M |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 126.00K | 126.00K | 126.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 0.00 | 10.00M |
| Cash from Investing | -3.61M | -3.91M | -3.07M | -3.77M | 7.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.13M | -1.06M | -21.03M | -20.88M | -20.65M |
| Issuance of Common Stock | 15.27M | 17.38M | 32.64M | 28.54M | 17.70M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -50.00K | -50.00K | -50.00K | 0.00 | -232.00K |
| Cash from Financing | 14.09M | 16.27M | 11.56M | 7.66M | -3.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.80M | -9.46M | -16.10M | -19.74M | -6.13M |